FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 1, 1997.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:

1. MBNA Corporation, Wilmington, Delaware; to acquire 100 percent of the voting shares of MBNA Amercia Bank (Delaware), Wilmington, Delaware.

Board of Governors of the Federal Reserve System, October 3, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26736 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 3, 1997.

A. Federal Reserve Bank of Atlanta (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. Trust No. 3 Under Will of Charles Henderson, Troy, Alabama; to acquire at least 79 percent of the voting shares of Pea River Capital Corporation, Elba, Alabama, and thereby indirectly acquire The Peoples Bank of Coffee County, Elba, Alabama.

B. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. Sparta Union Bancshares, Inc., Sparta, Wisconsin; to become a bank holding company by acquiring 100 percent of the voting shares of Union National Bnk & Trust Company, Sparta, Wisconsin.

C. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. First National Bancorp, Inc., Green Forest, Arkansas; to become a bank holding company by acquiring 100 percent of the voting shares of First National Bank in Green Forest, Green Forest, Arkansas.

D. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. Midland First Financial Corporation, Lee's Summit, Missouri; to become a bank holding company by acquiring 100 percent of the voting shares of Midland Bank, Lee's Summit, Missouri.

Board of Governors of the Federal Reserve System, October 6, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26854 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 23, 1997.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. Citizens Development Co., Billings, Montana; to engage *de novo* through its subsidiary, Citizens Development Co., Billings, Montana, and thereby engage in making and servicing loans, pursuant to § 225.28(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, October 3, 1997.

William W. Wiles,

Secretary of the Board.

[FR Doc. 97–26735 Filed 10–8–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Meetings

Notice of two meetings of the National Bioethics Advisory Commission (NBAC), one each of its genetics and human subjects subcommittees, and a brief joint session of the full Commission.

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of two meetings of the National Bioethics Advisory Commission and a brief joint session of the full Commission. Commission members will discuss the protection of the rights and welfare of human subjects in research including decisionally and/or cognitively impaired populations and will address the use of genetic information involved in tissue storage. The meetings are open to the public and opportunities for statements by the public will be provided.

Dates/times	Locations
Human Subjects Subcommittee, October 19, 1997, 7:30 am–4:30 pm.	National Institutes of Health, 9000 Rockville Pike, Building 31, 6th Floor, Conference Room 10, Bethesda, Maryland 20892.
11:30 am–1:30 pm	Full Commission Meeting, Conference Room 10.
Genetics Subcommittee, October 19, 1997, 7:30 am–4:30 pm.	National Institutes of Health, 9000 Rockville Pike, Building 31, 6th Floor, Conference Room 9, Bethesda, Maryland 20892.

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975 on October 3, 1995 for an initial two years. An amendment to Executive Order 12975, dated May 16, 1997, extended the term of the Commission for an additional two years. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council and other entities on bioethical issues arising from the research on human biology and behavior, and in the applications of that research including clinical applications.

Public Participation

All meetings are open to the public with attendance limited by the availability of space. Members of the public who wish to present oral statements should contact Ms. Patricia Norris by telephone, fax machine, or mail as shown below prior to the meeting as soon as possible. Individuals unable to make oral presentations are encouraged to mail or fax their comments to the NBAC staff office for distribution to the subcommittee or Commission members and inclusion in the public record. Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Patricia Norris, National Bioethics Advisory Commission, MSC–7508, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892–7508, telephone 301–402–4242, fax number 301–480–6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, Acting, National Bioethics Advisory Commission.

[FR Doc. 97–26866 Filed 10–8–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Minimizing Medical Product Errors—A Systems Approach; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop entitled ''Minimizing Medical Product Errors—A Systems Approach.'' The purpose of this workshop is to provide a forum for an open exchange with industry, health professionals, consumers, and others on issues relating to minimizing the potential for medical product errors due to similarities in drug names, similar labeling, design and packaging of human drugs, biologics, blood/blood products, vaccines, and medical devices.

DATES: The public workshop will be held on Thursday, January 8, 1998, 7:30 a.m. to 6 p.m. An open public hearing to present comments, 4:15 p.m. to 5:45 p.m. Submit written abstracts by November 7, 1997. Submit written notices of participation by December 5, 1997. There is no registration fee for this workshop, however, because seating is limited interested persons are encouraged to register by December 15, 1997.

ADDRESSES: The public workshop will be held at Natcher Auditorium, National Institutes of Health, 45 Center Dr., Bethesda, MD. Submit written abstracts and notices of participation to Mary C. Gross (address below).

FOR FURTHER INFORMATION CONTACT:

For general information: Mary C. Gross, Office of External Affairs (HF–60), Food and Drug Administration, 5600 Fishers Lane, rm. 14C–03, Rockville, MD 20857, 301–827–3440, FAX 301–594–0113, e-mail MGROSS@BANGATE.FDA.GOV.

For information regarding the scientific paper selection process: Jerry Phillips, Center for Drug Evaluation and Research, 7500 Standish Pl., rm. N271, Rockville, MD 20852, 301–827–5840, FAX 301–594–0183, e-mail PHILLIPSJ@A1@FDACD.

SUPPLEMENTARY INFORMATION:

I. Background

FDA will explore the extent of user error occurring with FDA-regulated products; collect data to help FDA determine what methods, if any, already exist to assess the potential for medical product errors; hear discussion from outside groups about the appropriate role for FDA in minimizing medical product errors; and discuss how the agency can effectively collaborate in minimizing user errors.

II. Submission of the Abstracts

For purposes of discussion at the workshop, FDA is requesting abstracts that discuss how best to minimize the incidence of user error with FDA-regulated products. FDA will select a limited number of abstracts that contain information on what methods, if any, already exist to assess the potential for user error in relation to labeling, packaging, and design of FDA-regulated products for formal presentation at the workshop.

The abstracts should be printed (typewritten or computer) within the confines of an 8 1/2 x 11-inch page of white paper. All lines should be single spaced with a three-letter indent for each paragraph. The title should be brief and capitalized. The authors name(s) should then be listed, underlining each, then list agency, institution, or facility involved.